Medtech intelligence platform AcuityMD has secured $80 million in Series C funding, bringing its total capital raised to over $160 million and pushing its post-money valuation to $955 million. The round, led by existing investor StepStone Group with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management, highlights a growing venture capital appetite for verticalized software architectures over horizontal AI models.
The Boston-based startup has established a highly defensible data moat by aggregating fragmented healthcare signals—including insurance claims databases, FDA filings, and government records—into a proprietary medtech ontology. This continuously enriched knowledge graph maps the complex, highly localized relationships between physicians, healthcare facilities, networks, procedure volumes, and reimbursement dynamics. Hunter Somerville, Partner at StepStone Group, emphasized the value of this architecture, noting that "the depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable."
AcuityMD, which counts 16 of the top 20 global medtech enterprises among its 400 clients, has already surfaced more than $34 billion in pipeline opportunities for its users. The newly injected capital is earmarked to fund a transition from passive data indexing to autonomous workflows through its new agentic AI engine, AcuityAI. Currently in open beta, the tool is designed to instantly build field-ready territory plans and prioritize surgeon targets for sales reps.
The funding will also drive an aggressive total addressable market (TAM) expansion, moving the software past its core sales operations use case to target marketing, leadership, and regulatory teams across the entire medical device product lifecycle. "AI will transform medtech, but only with the right context, deeply embedded in the workflows where decisions are made," stated Mike Monovoukas, CEO and Co-Founder of AcuityMD.
